Pharmaceuticals, Biotechnology and Life Sciences
Premaitha Health has signed an agreement to offer the IONA test across Egypt. As a result of, Premaitha has secured…
Premaitha Health has announced that the IONA test has been approved by Brazil’s regulatory authority, Agência Nacional de Vigilância Sanitária…
Premaitha Health, a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its European…
Premaitha Health, an international molecular diagnostics group focused on prenatal testing, has acquired Taiwanese Yourgene Bioscience.
Premaitha has signed four-year Master Procurement Agreement (the “MPA”) with a European diagnostics services group to install the IONA test in at least two of the Groups’s laboratories.
Premaitha Health’s shareholders have approved the acquisition of Yourgene, a bioinformatics specialist based in Taiwan. The purchase was approved on Tuesday afternoon.
Premaitha has announced the conditional acquisition of the entire issued share capital of Yourgene.
Premaitha Health has gotten UK’s Department of Health approval to make non-invasive prenatal tests (“NIPT”)
Premaitha Health has issued 940,000 options over ordinary shares under the Company’s unapproved share option scheme to two employees.
David Evans, Non-executive Chairman, has stepped down from the Board with immediate effect.